Free Trial
NASDAQ:ASMB

Assembly Biosciences (ASMB) Stock Price, News & Analysis

Assembly Biosciences logo
$11.15 +0.03 (+0.27%)
Closing price 04:00 PM Eastern
Extended Trading
$11.39 +0.24 (+2.14%)
As of 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Assembly Biosciences Stock (NASDAQ:ASMB)

Key Stats

Today's Range
$10.80
$11.89
50-Day Range
$11.12
$17.49
52-Week Range
$10.89
$19.93
Volume
20,355 shs
Average Volume
24,349 shs
Market Capitalization
$70.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00
Consensus Rating
Moderate Buy

Company Overview

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Remove Ads

Assembly Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

ASMB MarketRank™: 

Assembly Biosciences scored higher than 76% of companies evaluated by MarketBeat, and ranked 231st out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Assembly Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Assembly Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Assembly Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Assembly Biosciences are expected to decrease in the coming year, from ($6.87) to ($7.64) per share.

  • Price to Book Value per Share Ratio

    Assembly Biosciences has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Assembly Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    0.51% of the float of Assembly Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Assembly Biosciences has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Assembly Biosciences has recently increased by 25.55%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Assembly Biosciences does not currently pay a dividend.

  • Dividend Growth

    Assembly Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.51% of the float of Assembly Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Assembly Biosciences has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Assembly Biosciences has recently increased by 25.55%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Assembly Biosciences has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Assembly Biosciences this week, compared to 10 articles on an average week.
  • Search Interest

    Only 1 people have searched for ASMB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Assembly Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,983.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 5.10% of the stock of Assembly Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 19.92% of the stock of Assembly Biosciences is held by institutions.

  • Read more about Assembly Biosciences' insider trading history.
Receive ASMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ASMB Stock News Headlines

Trump’s Tariff Horrors (your golden opportunity)
With new tariffs on the way, millions of Americans are having nightmares about how much they'll have to spend. But here's the secret they're not talking about… A historic $72 trillion wealth transfer is already underway and it's creating a tidal wave of opportunity for people who know what to do.
Assembly Biosciences reports positive Phase 1a results in genital herpes
H.C. Wainwright stays Neutral on Assembly Biosciences after ABI-4334 data
See More Headlines

ASMB Stock Analysis - Frequently Asked Questions

Assembly Biosciences' stock was trading at $15.78 on January 1st, 2025. Since then, ASMB stock has decreased by 29.3% and is now trading at $11.15.
View the best growth stocks for 2025 here
.

Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($4.92) earnings per share for the quarter, beating the consensus estimate of ($6.84) by $1.92. The biopharmaceutical company had revenue of $6.25 million for the quarter. Assembly Biosciences had a negative trailing twelve-month return on equity of 121.46% and a negative net margin of 144.05%.

Assembly Biosciences shares reverse split on Monday, February 12th 2024. The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Assembly Biosciences' top institutional shareholders include Gilead Sciences Inc. (34.74%), Renaissance Technologies LLC (1.49%), Peapod Lane Capital LLC (0.99%) and B Group Inc. (0.80%). Insiders that own company stock include Alexander Schornstein, John G Mchutchison, Jason A Okazaki, Nicole S White, Michael P Samar, William E Iv Delaney, Michael Houghton, Jeanette M Bjorkquist and Luisa M Stamm.
View institutional ownership trends
.

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Assembly Biosciences investors own include Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
11/04/2021
Today
3/10/2025
Next Earnings (Estimated)
3/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ASMB
Employees
100
Year Founded
2005

Price Target and Rating

Average Stock Price Target
$35.00
High Stock Price Target
$35.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+212.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-61,230,000.00
Net Margins
-144.05%
Pretax Margin
-142.50%

Debt

Sales & Book Value

Annual Sales
$28.33 million
Price / Cash Flow
N/A
Book Value
$7.50 per share
Price / Book
1.49

Miscellaneous

Free Float
6,032,000
Market Cap
$71.19 million
Optionable
Optionable
Beta
0.62

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ASMB) was last updated on 3/10/2025 by MarketBeat.com Staff
From Our Partners